Evidence map›Paper›PMID 25830772›Full record

ArticlePloS one2015

18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY.

Jae Yong Choi, Chul Hyoung Lyoo, Jin Su Kim, Kyeong Min Kim, Jee Hae Kang, Soo-Hee Choi, Jae-Jin Kim, Young Hoon Ryu

Erratum issuedOpen access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Biodistribution and Radiation Dosimetry of [Molecular imaging and biology · 2016
    Trial
  2. Article
  3. Review
  4. Evidence For Cannabidiol Modulation of Serotonergic Transmission in a Model of Osteoarthritis viaInternational journal of innovative research in medical science · 2022
    Article
  5. Radiotracers for the Central Serotoninergic System.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  6. Review
  7. Comparison of [Pharmacology research & perspectives · 2016
    Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Jae Yong ChoiDepartment of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Chul Hyoung LyooDepartment of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Jin Su KimMolecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Kyeong Min KimMolecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Jee Hae KangDepartment of Chemistry and Biochemistry, Swarthmore College, 500 College Avenue Swarthmore, PA, United States of America.
Soo-Hee ChoiDepartment of Psychiatry and Institute of Human Behavioral Sciences, Seoul National University College of Medicine, Seoul, Korea.
Jae-Jin KimDepartment of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea.
Young Hoon RyuDepartment of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Korea Institute of Radiological and Medical Sciences · KRGangnam Severance Hospital · KRSeoul National University · KRSwarthmore College · USYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe purpose of this research is to evaluate the prospects for the use of 4-(trans-18F-fluoranylmethyl)-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexane-1-carboxamide (18F-Mefway) in comparison to 18F-trans-4-fluoro-N-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide (18F-FCWAY) for the quantification of 5-HT1A receptors in human subjects.

methodFive healthy male controls were included for two positron emission tomography (PET) studies: 18F-FCWAY PET after the pretreatment with 500 mg of disulfiram and two months later, 18F-Mefway PET without disulfiram. Regional time-activity curves (TACs) were extracted from nine cortical and subcortical regions in dynamic PET images. Using cerebellar cortex without vermis as reference tissue, in vivo kinetics for both radioligands were compared based on the distribution volume ratio (DVR) calculated by non-invasive Logan graphical analysis and area under the curve ratio of the TACs (AUC ratio).

resultAlthough the pattern of regional uptakes in the 18F-Mefway PET was similar to that of the 18F-FCWAY PET (highest in the hippocampus and lowest in the cerebellar cortex), the amount of regional uptake in 18F-Mefway PET was almost half of that in 18F-FCWAY PET. The skull uptake in 18F-Mefway PET was only 25% of that in 18F-FCWAY PET with disulfiram pretreatment. The regional DVR values and AUC ratio values for 18F-Mefway were 17-40% lower than those of 18F-FCWAY. In contrast to a small overestimation of DVR values by AUC ratio values (< 10%) in 18F-FCWAY PET, the overestimation bias of AUC ratio values was much higher (up to 21%) in 18F-Mefway PET.

conclusionAs 18F-Mefway showed lower DVR values and greater overestimation bias of AUC ratio values, 18F-Mefway may appear less favorable than 18F-FCWAY. However, in contrast to 18F-FCWAY, the resistance to in vivo defluorination of 18F-Mefway obviates the need for the use of a defluorination inhibitor. Thus, 18F-Mefway may be a good candidate PET radioligand for 5-HT1A receptor imaging in human.

Indexed as

AdultArea Under CurveBrainCyclohexanesFluorine RadioisotopesHumansMalePiperazinesPositron-Emission TomographyPyridinesRadiopharmaceuticalsReceptor, Serotonin, 5-HT1AROC CurveSkullTomography, X-Ray ComputedCyclohexanesFluorine RadioisotopesmefwayN-(2-(4-(2-methoxyphenyl)piperazino))-N-(2-pyridinyl) trans-4-fluorocyclohexanecarboxamidePiperazinesPyridinesRadiopharmaceuticalsReceptor, Serotonin, 5-HT1A

Identifiers

PMID25830772
PMCPMC4382022
OpenAlexW2087844899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.